Control Print's Guwahati capex breaks prior promise, pharma pilots still in testing
The core coding business is steady with 16% growth, but divergence between earlier guidance and current execution on new ventures raises credibility questions.
What's new
- Guwahati capex for core coding production committed despite prior no-major-capex assurance.
- Pharma Track and Trace pilots still in final-stage testing, previously undisclosed setback.
- V-Shapes Italy losses narrowing but still €1.5M; strategic IP pivot funded by ₹7-10 cr annual royalty.
Why this matters
Management's forecasting credibility faces a test after a surprise capex and a pharma pilot delay that were not flagged earlier. The core 16% growth is intact, but the new ventures' timelines slipping could postpone the higher-margin IP-led transition.
What we're watching
- Detailed Guwahati capex quantum and timeline.
- Pharma pilot commercialisation date.
- V-Shapes Italy's path to breakeven.
The full read
Control Print's core coding and marking business delivered a steady 16% standalone revenue growth and improved gross margins, confirming the base business is solid. The market-moving news from its May 2026 concall, however, lies in a surprising capital expenditure commitment at the new Guwahati facility — directly contradicting prior assurances of no major capex for 1-2 years. Additionally, the company disclosed that critical Track and Trace pharma pilots are still in final-stage testing after a previously undisclosed setback, implying a delay in what was expected to be a growth catalyst. On the international side, V-Shapes Italy's loss is narrowing from €2.5M in FY26 to an expected €1.5M in FY27, but the bleed continues. The strategic IP ownership pivot, funded by annual royalty payments of ₹7-10 crore, positions Control Print for higher-margin proprietary technology, but the credibility gap between past guidance and current execution on new ventures is the key takeaway for investors.